


Journal Pre-proof

The disease burden of Delta and Omicron variants of SARS-CoV-2 in a Predominantly Vaccinated and healthy cohort

Parham Sendi, Mattia Branca, Annina Elisabeth Büchi, Nadja Widmer, Aaron J. Tande, Peter Gowland, for the PoliCOV-19 study



PII: S1198-743X(22)00456-6

DOI: <https://doi.org/10.1016/j.cmi.2022.08.019>

Reference: CMI 3055

To appear in: *Clinical Microbiology and Infection*

Received Date: 11 July 2022

Revised Date: 24 August 2022

Accepted Date: 27 August 2022

Please cite this article as: Sendi P, Branca M, Büchi AE, Widmer N, Tande AJ, Gowland P, for the PoliCOV-19 study, The disease burden of Delta and Omicron variants of SARS-CoV-2 in a Predominantly Vaccinated and healthy cohort, *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2022.08.019>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

1 **Revision - Letter** – Version 21 August 2022

2

3 **The Disease Burden of Delta and Omicron Variants of SARS-CoV-2 in a Predominantly**
4 **Vaccinated and Healthy Cohort**

5

6 Parham Sendi,^{1*} Mattia Branca,² Annina Elisabeth Büchi,³ Nadja Widmer,⁴ Aaron J. Tande,⁵

7 Peter Gowland,⁴ for the PoliCOV-19 study⁶.

8

9 ¹Institute for Infectious Diseases, University of Bern, Bern, Switzerland.

10 ²CTU Bern, University of Bern, Bern, Switzerland.

11 ³Department of Emergency Medicine, Inselspital, Bern University Hospital, University of
12 Bern, Bern, Switzerland.

13 ⁴Interregional Blood Transfusion Swiss Red Cross, Bern, Switzerland.

14 ⁵Division of Public Health, Infectious Diseases, and Occupational Medicine Mayo Clinic,
15 Rochester, MN, USA.

16 ⁶The full list of authors contributing to the PoliCOV-19 study are displayed in the
17 Supplementary Material.

18

19 ***Correspondence:** Parham Sendi, MD, ORCID: 0000-0002-7347-6312

20 Institute for Infectious Diseases, University of Bern, Friedbühlstrasse 51, 3001, Bern,
21 Switzerland.

22 parham.sendi@ifik.unibe.ch

23 Tel: +41 31 638 69 86; Fax: +41 31 638 67 86

24

25 **Manuscript Details**

26 Word counts: main text 809

27 References: 5

28 Figure: 1

29 Supplementary Material

30

31 **Keywords**

32 SARS-CoV-2; anti-S-antibodies; anti-NCP-antibodies; COVID-19 seroprevalence.

Journal Pre-proof

33 To The Editor

34

35 Since February 2021, we have been studying the seroprevalence of anti-SARS-CoV-2
36 antibodies in a cohort of individuals employed by the Cantonal Police Bern in Switzerland.
37 The baseline study (February 2021), the 3-month (May 2021), and 6-month (September 2021)
38 follow-up visits correspond to the first, second, and third cross-sectional analyses of the
39 cohort, as previously reported [1, 2] (**Supplementary Figure 1**). Here, we present the SARS-
40 CoV-2 infection and vaccination rates at the 9-month (fourth cross-sectional analysis, in
41 December 2021) and 12-month visits (fifth cross-sectional analysis, in March/April 2022)
42 and estimate the SARS-CoV-2 burden within the cohort after the Delta and Omicron surges.

43

44 The cohort population includes 1022 study participants. The mean age is 41 (SD 8.8) years,
45 72% are male, and 76% have no comorbidity. The serological methods and questionnaires
46 were used as previously reported [1, 2] (**Supplementary Material**).

47 From late June 2021, the SARS-CoV-2 Delta variant (B.1.617.2, all subvariants AY) was
48 dominant in Switzerland until its replacement by the Omicron sublineages BA.1 and BA.2,
49 which became predominant from mid/late December 2021 till mid-February and the
50 beginning of April 2022, respectively (**Supplementary Figure 2**).

51

52 The SARS-CoV-2 infection rate per 3 months was defined as (i) seroconversion of anti-NCP
53 antibodies or (ii) a self-reported PCR test from a nasopharyngeal or saliva sample. The
54 proportion of positive agreement (PPA) between the two modalities was evaluated and
55 adjusted when seroconversion occurred at later follow-up visits. To estimate the SARS-CoV-
56 2 burden (including the disease and non-disease consequences), we evaluated the proportion

57 of study participants who reported symptoms, sought a medical doctor, required
58 hospitalization, and missed work or police academy because of COVID-19.

59

60 At the 9-month visit, the seroprevalence of anti-NCP antibodies was 19.1% (n=188/985; 95%
61 confidence interval [CI] 16.7%–21.5%). Anti-NCP seroconversion was identified in 4.8% of
62 samples (n=47, 95% CI 3.6%–6.3%). Twenty-one individuals without seroconversion
63 reported a positive PCR test result from a nasopharyngeal or saliva sample, 16 of them
64 showed seroconversion at the 12-month visit. Hence, the infection rate within the previous 3
65 months was 6.9% (68/985; 95% CI 5.5%–8.7%), and the adjusted PPA for PCR test results
66 and seroconversion was 92.6% (63/68).

67 At the 12-month visit, the seroprevalence of anti-NCP antibodies was 51.6% (n=499/967;
68 95% CI 48.5%–54.7%). Anti-NCP seroconversion was identified in 32.7% of samples
69 (n=316, 95% CI 29.2%–35.1%). Sixty individuals without seroconversion reported positive
70 PCR test results. After excluding the 16 individuals with a positive PCR test at the 9-month
71 and seroconversion at the 12-month visit, the infection rate within the previous 3 months was
72 37.2% (360/967, 95% CI 34.2%–40.3%). PPA was 83.3% (300/360) and could not be
73 adjusted for late seroconversion, because the study ended after the fifth cross-sectional
74 analysis.

75

76 To assess these infection rates in view of 2 parameters for protective immunity, we evaluated
77 (i) vaccine rates and (ii) the presence of anti-Spike(S) antibodies 2 weeks prior to the start of
78 each cross-sectional analysis (**Figure**). The increase in vaccination rate for the first (1.9%) or
79 second (3.1%) dose between the 9- and 12-month visit was minimal. The proportion of
80 individuals with a booster, however, rose from 0.6% to 60% 8 weeks and to 63.3% 2 weeks

81 prior to the 12-month visit. The corresponding results of the anti-S-antibodies are shown in
82 the **Figure**.

83

84 At 12-month-visit, we found no statistically significant difference between infection rates
85 among individuals with a booster vaccine dose (36.6%; 242/661) and those without (38.6%,
86 118/306; difference 2.0%, 95% CI 4.6%–8.5%, $P = 0.559$).

87

88 At the 9-month visit, 0.5% of the study participants reported having had no symptoms, and at
89 the 12-month visit, 2.0% did so. At the 9-month-visit, 6.1% reported that they sought a doctor
90 appointment, 16.3% that they missed working days (or school days at the police academy),
91 and 1.2% that they were hospitalized because of COVID-19. After the 12-month-visit, the
92 proportions were 7.3%, 33.4%, and 1.8%, respectively. The median numbers of missed
93 working days were 7 (IQR 2–10) days during the Delta surge and 4 (IQR 2–5) days during
94 the Omicron surge.

95

96 This study evaluated the burden of the Delta and Omicron surges in a healthy population
97 cohort with a relatively high vaccination rate. During the Omicron surge, an infection rate of
98 37.2% (95% CI 34.2%–40.3%) was noted in the cohort within 3 months, despite the fact that
99 more than 88% had 2 doses of mRNA vaccine and more than 63% had an additional booster
100 dose. The seroprevalence of anti-NCP antibodies rose from 15% in September 2021 to 19%
101 in December 2021 to 52% in March/April 2022 (**Supplementary Figure 1**). The latter
102 number is likely underestimated, considering that 60 (6.2%) study participants tested positive
103 for SARS-CoV-2 in a nasopharyngeal or saliva sample and did not (yet) reveal
104 seroconversion at the time of serum sampling.

105

106 The high infection rate observed from January to March/April 2022 is likely due to the
107 transmissibility and immunologic escape properties of the Omicron variant [3]. The disease
108 and non-disease consequences of the Delta and Omicron variants in a defined cohort has not
109 previously been quantified. From a disease perspective, these data reinforce previous findings
110 and support information statements by health authorities that COVID-19 remains protective
111 against hospitalization and severe infection [4]. From a non-disease perspective, considerable
112 work absences within 3 months were observed, illustrating the disruption potential of
113 Omicron for emergency service providers.

114

115 Because we found no difference in infection rate between non-boosted and boosted
116 individuals within the 3-month window at which the Omicron variants were predominant,
117 and because among the boosted group 95% received their third vaccine dose 8 weeks prior to
118 the cross-sectional analyses, the results suggests that protection from non-severe Omicron
119 infection is not durable. However, we are unable to confirm this conclusion, because we did
120 not inquiry the precise infection dates in the questionnaires.

121

122 The data provided in this study are highly relevant for the preparation and management of
123 large-scale absences in the workplace for both the public and private sectors [5]. They
124 indicate that the SARS-CoV-2 burden may shift from hospitalization because of severe
125 disease to work shortage because of Omicron variants.

126 Ethics

127 All participants signed written informed consent prior to enrollment in the PoliCOV-19
128 study. The collection of coded data and the design of the work were approved by the
129 Cantonal Research Ethics Commission of Bern, Switzerland (ID-2020-02650). Trial
130 registration: ClinicalTrials.gov NCT04643444.

131

132 Funding

133 There was no funding via a grant or an external institution. The manufacturer of the
134 electrochemiluminescence immunoassay tests (Roche) provided no funding for this study, as
135 the test was commercially purchased by the investigators. The study was funded in part by
136 the Cantonal Police of Bern, Bern, Switzerland. The Institute for Infectious Diseases of the
137 University of Bern and the Interregional Blood Transfusion, Swiss Red Cross, Bern,
138 Switzerland, supported the study by providing working hours of their employees specifically
139 for this study and by providing material and consumables at cost or for free.

140

141 Conflict of Interest

142 None

143

144 Acknowledgments

145 The full list of authors of the PoliCOV-19 study is displayed in the supplementary material.
146 We thank the numerous volunteers and the study team members from the affiliated and other
147 institutions for their help in conducting the study, including Medbase Zweisimmen, Hôpital
148 du Jura Bernois SA, Saint-Imier, Medicentre Moutier, and numerous others. We thank Flora
149 Babongo Bosombo from CTU, University of Bern, Bern, Switzerland, for her statistical
150 support. We thank Simeon Brülisauer for his dedicated efforts in managing the study. We

151 thank all the employees of the Cantonal Police Bern for participating. BioMedical Editor, St
152 Albert, Alberta, Canada, provided English-language editing.

Journal Pre-proof

153 **Figure 1 legend**

154 **Vaccine rates and the presence of anti-S antibodies of the police cohort in one year**
155 **study period.**

156 The blue bars (anti-Spike-antibody titers) are inserted at dates 2 weeks prior to the start of
157 each cross-sectional analysis. The time points for anti-S antibodies are biased by the per
158 protocol predefined serum sampling time points. Prior to the 9-month visit (i.e., after the third
159 cross-sectional analysis), 87.0% of individuals displayed anti-S antibodies with a titer ≥ 0.8
160 U/mL, and 81% with a titer > 250 U/mL. Prior to the fifth cross-sectional analysis (i.e., after
161 the fourth cross-sectional analysis), 93.0% of individuals displayed anti-S antibodies with a
162 titer ≥ 0.8 U/mL, and 88% with a titer > 250 U/mL.

163 The red, green and purple curves illustrated the cumulative vaccine rates over time. The self-
164 reported vaccine dates are collected from questionnaires. The vaccine rates are the values 2
165 weeks prior to the start of each cross-sectional analysis.

166 **References**

- 167 1. Sendi P, Baldan R, Thierstein M, et al. A Multidimensional Cross-Sectional Analysis of
168 Coronavirus Disease 2019 Seroprevalence Among a Police Officer Cohort: The PoliCOV-19
169 Study. *Open Forum Infect Dis* **2021**; 8(12): ofab524.
- 170 2. Sendi P, Thierstein M, Widmer N, et al. Serosurveillance after a COVID-19 vaccine campaign
171 in a Swiss police cohort. *Immunity, Inflammation and Disease* **2022**; 10(7): e640.
- 172 3. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global
173 spread of SARS-CoV-2 variants of concern as at June 2021. *Euro Surveill* **2021**; 26(24).
- 174 4. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation
175 and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in
176 England: a cohort study. *Lancet* **2022**; 399(10332): 1303-12.
- 177 5. CIPD. Absence management. Resources and useful links on managing absence related to
178 COVID-19, including advice on self-isolation and sick pay. Available at:
179 <https://www.cipd.co.uk/knowledge/coronavirus/absence-management>. Accessed June 24,
180 2022.

181

